Publications: Our research

Filter
Research Area
Technology
Resource type
Category
142 results found
Jul 14, 2024
Publication
Novavax led
microorganisms
COVID-19, Matrix-M™ adjuvant
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity
Raj Kalkeri, Ph.D., Mingzhu Zhu, Ph.D., Shane Cloney-Clark B.Sc, et al.
Jul 5, 2024
Preprint
Novavax led
medRxiv
COVID-19, Matrix-M™ adjuvant
Short-Term Relative Effectiveness of Homologous NVX-CoV2373 and BNT162b2 COVID-19 Vaccinations in South Korea
Eunseon Gwak, Seung-Ah Choe, Erdenetuya Bolormaa, et al.
Jun 25, 2024
Preprint
Novavax led
medRxiv
COVID-19, Matrix-M™ adjuvant
Reactogenicity Differences between COVID-19 Vaccines: A Prospective Observational Study in the United States and Canada
Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
Apr 23, 2024
Publication
Collaborative
BMC Medicine
Malaria, Matrix-M™ adjuvant
A Pfs48/45‑based vaccine to block Plasmodium falciparum transmission: phase 1, open‑label, clinical trial
M. Alkema, M. J. Smit, C. Marin‑Mogollon, et al.
Apr 20, 2024
Publication
Novavax led
Journal of Virological Methods
COVID-19, Matrix-M™ adjuvant
Validation of a severe acute respiratory syndrome coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity
Stephanie Hamilton, Mingzhu Zhu, Shane Cloney Clark, et al.
Apr 6, 2024
Publication
Novavax led
Vaccines
COVID-19, Matrix-M™ adjuvant
Characteristics and Outcomes for Recipients of NVX-CoV2373: A Real-World Retrospective Study in Germany
Lucie Kutikova, James T. Brash, Kawitha Helme, et al.
Mar 16, 2024
Publication
Novavax led
Vaccine
COVID-19, Matrix-M™ adjuvant
Benefit–risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373)
Jonathan Fix, T. Christopher Mast, Katherine Smith, et al.
Mar 6, 2024
Publication
Novavax led
The Lancet Infectious Diseases
COVID-19, Matrix-M™ adjuvant
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
Chijioke Bennett, Wayne Woo, Mark Bloch, et al.
Feb 29, 2024
Publication
Novavax led
microorganisms
COVID-19, Matrix-M™ adjuvant
A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation
Zhaohui Cai, Raj Kalkeri, Mingzhu Zhu, et al.
Feb 19, 2024
Publication
Novavax led
Clinical Infectious Diseases
COVID-19, Matrix-M™ adjuvant
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-cov2373 Vaccine
Dean Follmann, Allyson Matej, Michael P. Fay, et al.